ÂÜÀòÂÒÂ×

Madan Jagasia, M.D., M.S., is Obsidian’s Chief Executive Officer. Dr. Jagasia is a highly experienced physician executive with an extensive oncology and cell therapy-focused clinical background and deep industry experience developing tumor-infiltrating lymphocyte (TIL) treatments for cancer. Prior to joining Obsidian, Dr. Jagasia was Executive Vice President, Medical Affairs at Iovance Biotherapeutics, where he was responsible for managing national medical affairs, strategic congress planning, advocacy, strategic alliances and external research collaborations. Before Iovance, he was Chief Medical Officer and Executive Medical Director of Cancer Patient Care Center, Vanderbilt-Ingram Cancer Center (VICC), where he co-led Translational Research and Interventional Oncology Research Program at VICC. Dr. Jagasia began his career as a faculty member in the Division of Hematology-Oncology at Vanderbilt University Medical Center. Dr. Jagasia has his M.B.B.S from the GS Medical College & KEM Hospital, an M.S. and a Master of Management in Health Care from Vanderbilt University.